FTC K-Dur Case Incorrectly Defines Market, Judge Says In Ruling For Schering
Executive Summary
Merck-Medco's decision not to separately list Schering-Plough's K-Dur on its formulary is evidence that the drug is therapeutically substitutable and competes with other versions of potassium chloride, an administrative law judge said
You may also be interested in...
“Reverse” Payments Anti-Competitive In K-Dur Pact But Not All Cases – FTC
The Federal Trade Commission's ruling that the settlement between Schering-Plough and Upsher-Smith relating to K-Dur is anti-competitive stops short of defining all "reverse" payments as illegal
“Reverse” Payments Anti-Competitive In K-Dur Pact But Not All Cases – FTC
The Federal Trade Commission's ruling that the settlement between Schering-Plough and Upsher-Smith relating to K-Dur is anti-competitive stops short of defining all "reverse" payments as illegal
K-Dur Case: Reverse Payments Not “Established” Antitrust Violations – Judge
Reverse payments from brand to generic companies in patent settlements are not "established" antitrust violations, an administrative law judge said in dismissing the Federal Trade Commission's antitrust case against Schering-Plough regarding K-Dur